Tara Mahon

This inventor holds 6 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Immunocore Limited, Avidex Limited. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tara Mahon. Retrieved from https://idiyas.com/inventor/tara-mahon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 3.7

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

Years Active: 2022-2026

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698316 - ENGINEERED IMMUNE-MOBILIZING T-CELL RECEPTORS WITH ENHANCED AFFINITY FOR HIV-1 GAG (2026-08-04),

2. 12018062 - T cell receptors (2024-06-25),

3. 11718657 - T cell receptors (2023-08-08),

4. 11505590 - T cell receptors (2022-11-22),

5. 11440944 - Engineered immune-mobilizing T-cell receptors with enhanced affinity for HIV-1 Gag (2022-09-13),

6. 11427624 - T cell receptors (2022-08-30),

Title: Innovations in Immunotherapy: The Contributions of Tara Mahon

Introduction

Tara Mahon is a prominent inventor based in Abingdon, GB, known for her significant contributions to the field of immunotherapy. With a total of five patents to her name, she has made remarkable strides in the development of T cell receptors that target cancer antigens.

Latest Patents

Her latest patents focus on T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide SLLQHLIGL, derived from the germline cancer antigen PRAME. These TCRs may include non-natural mutations within the alpha and/or beta variable domains compared to a native PRAME TCR. The TCRs developed by Mahon are particularly suitable for use as novel immunotherapeutic reagents in the treatment of malignant diseases.

Career Highlights

Tara Mahon has established herself as a key figure in the field of immunotherapy through her innovative research and development efforts. She works at Immunocore Limited, where her expertise in T cell receptor technology is utilized to advance cancer treatment options.

Collaborations

Mahon collaborates with notable colleagues, including Nathaniel Ross Liddy and Philip William Addis, to further enhance the impact of her work in immunotherapy.

Conclusion

Tara Mahon's contributions to the field of immunotherapy through her innovative patents and collaborations highlight her role as a leading inventor in the fight against cancer. Her work continues to pave the way for new therapeutic approaches that could significantly improve patient outcomes.

Profile summary based on public USPTO records.